NCT03842228 2025-10-14CODNational Cancer Institute (NCI)Phase 1 Active not recruiting39 enrolled 15 charts
NCT02671435 2025-07-22A Study of Durvalumab (MEDI4736) and Monalizumab in Solid TumorsMedImmune LLCPhase 1/2 Active not recruiting383 enrolled 48 charts
NCT03439085 2024-07-09DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated CancersM.D. Anderson Cancer CenterPhase 2 Terminated41 enrolled 13 charts
NCT03162224 2022-08-25Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck CancerMedImmune LLCPhase 1/2 Completed35 enrolled 25 charts
NCT02805660 2021-04-06Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLCMirati Therapeutics Inc.Phase 1/2 Terminated83 enrolled 26 charts